New method in developing biomarkers for early diagnosis of diseases

Combinatory Chemistry is becoming a powerful tool in developing new theraputic & diagnostic agents. Similar to the inhibitory RNA aptamer against botulinum neurotoxin that I screened, the "peptoids library (artificially synthetic molecules)" has been recently screened to identify the potential candidates that stimulate more IgG binding in patietns than that in healthy person. Simply saying, you can inject the same peptoid into a "normal:diseased" pair of animals/human. If the immune system of the tested animals/human triggered an equal amount of IgG against the injected peptoid in both healthy and diseased group then this peptoid is useless. Therefore you can discard it and try the next peptoid candidate. You just keep repeating this process till you can find a peptoid candidate that trigger the immune system of diseased animal/human to produce at least three-fold higher levels of IgG than that in healthy animal/human. Thus this peptoid candidate becomes an useful biomarker to be used in early diagnosis of disease onset in other potential patients. Under this concept the identification of antigens of diseases become non-revelant. You don't even need to know the antigens of the immune response first. This new method can be applied in the early diagnosis of many neuro-degenerative diseases such as Alzheimer disease and Parkinson disease and so on.